# Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

> **NCT04911777** · PHASE2 · UNKNOWN · sponsor: **SyneuRx International (Taiwan) Corp** · enrollment: 90 (estimated)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **DRUG:** Pentarlandir™ UPPTA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04911777
- **Lead sponsor:** SyneuRx International (Taiwan) Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-24
- **Primary completion:** 2021-12
- **Final completion:** 2022-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911777, "Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04911777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*